Clarivate™

Comparing decision details with Add to basket

Cortellis HTA Intelligence

Create your own customized, exportable table comparing details on up to four HTA decisions. This is possible with data from the Market Access, Managed Entry Agreements, and Indications History analysis tables as well as the Clinical and Economic modules and from a Faceted Search result.

1. From any analysis or search result page, click the basket icons under the "Add" column for up to four decisions.

Agency: HAS

Status		Decision	Date	Drug Name	Indication	Line of therapy	Reason for decision (economic) ⓘ	Reason for decision (clinical)	Restrictions (Category)	PDF	Add
2 Events	🔍	Recommend	12/2010 - 07/2020							⧉	🛒
🔵			07/2020	gemtuzumab ozogamicin	For the treatment of adults and children aged ≥ 2 years with CD33-positive, relapsed or refractory AML, except acut ...	2+	N/A	Acceptable efficacy/effectiveness	No Restrictions	⧉	🛒
🔵			12/2010	histamine dihydrochloride	Ceplene maintenance therapy is indicated for adult patients with AML in first remission concomitantly treated with ...	Maintenance	N/A	Acceptable efficacy/effectiveness	No Restrictions	⧉	🛒
1 Event	🔍	Recommend (unknown restrictions)	04/2014	daunorubicin	For the treatment of AML in children, as part of a combination chemotherapy regimen.	1	N/A	Acceptable efficacy/effectiveness	Label unavailable	⧉	🛒
1 Event	🔍	Recommend with restrictions	07/2020	gemtuzumab ozogamicin	For the treatment of adult patients with AML who have an FLT3 mutation and are preferably eligible for treatment with gi ...	1+	N/A	Acceptable efficacy/effectiveness	Population	⧉	🛒

2. Scroll all the way back up to the top of the screen and click Compare.

Acute Myeloid Leukemia	gemtuzumab ozogamicin	HAS	July 2020	☰ ✖
Acute Myeloid Leukemia	histamine dihydrochloride	HAS	December 2010	☰ ✖
Acute Myeloid Leukemia	daunorubicin	HAS	April 2014	☰ ✖
Acute Myeloid Leukemia	gemtuzumab ozogamicin	HAS	July 2020	☰ ✖

🛒 (4)

‹ All Disease Conditions   Compare ›

3. The comparison table opens. Scroll down to read all the details in the table or Export to Excel.

    Note: Available options in the upper right corner will change according to your subscription.

Market Access Table   Clinical Strategy ⓘ   Economic Strategy ⓘ

daunorubicin Cerubidine, daunorubicin, DaunoXome ⬤

HAS - April 2014   ‹ Back   **Export to Excel**

Review Details		HAS - April 2014 - daunorubicin
Disease Conditions	☆	Acute Myeloid Leukemia
Indication under reimbursement review	☆	For the treatment of AML in children, as part of a combination chemotherapy regimen.
Agency	☆	HAS
Date	☆	April 2014
Review type	☆	STR
Evaluation type	☆	HAS Transparency Committee
Submission number/update number	☆	1
Does the review focus on a study question other than efficacy and/or cost-effectiveness?	☆	No

For more information contact Customer Service at **LS Product Support.**